SGLT1-sparing oral SGLT2 inhibitor prodrug
launched in India for diabetes, 100 mg BID
from mouse urine drug metabolite and opt.
Bioorg. Med. Chem., Jan. 22, 2021
Kissei Pharma / Toho University, JP
Remogliflozin etabonate
1 min read
The Kissei SGLT2 inhibitor prodrug, remogliflozin etabonate, is an SGLT1-sparing oral drug launched in 2019 in India for the treatment of type 2 diabetes. Interestingly, the lead for this drug was a metabolite identified from mouse urine after treatment with a Wyeth-Ayerst antihyperglycemic agent of previously unknown mechanism.
Search By Structure
- Remogliflozin etabonate
- GLPG2451
- BI 730357
- MLi-2
- “compound 1”
- “compound 5i”
- E7386
- NVS-BET-1
- “compound 16”
- JNJ-63576253
- Dosimertinib
- BMS-986242
- CCS1477
- Con B-1
Molecules of the Month
2023
2022
2021
2020